{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:59:18Z","timestamp":1781528358812,"version":"3.54.1"},"reference-count":242,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>As cancer survivorship increases, long-term opioid therapy (LTOT) has become more common in oncology, raising concerns about opioid-related harms. Buprenorphine offers unique pharmacologic advantages that position it as a safer alternative to full agonist opioids (FAOs), yet it remains underutilized in the management of cancer pain (CP). This article reviews the clinical rationale, supporting evidence, and practical considerations for using buprenorphine in managing CP throughout the cancer care continuum, with guidance from the NCCN Adult Cancer Pain Guideline Panel. This review synthesizes findings from pharmacologic research, clinical trials, guideline updates, and expert consensus. It examines the pharmacodynamics, dosing strategies, and safety of buprenorphine in vulnerable populations, as well as its potential to mitigate opioid-related complications. This review also discusses implementation barriers, including prescriber hesitancy, formulary restrictions, and stigma. Buprenorphine provides analgesia comparable to FAOs while reducing the risks of respiratory depression, opioid-induced hyperalgesia, hormonal disruption, and neurocognitive impairment. Buprenorphine may help reduce the neuroadaptive changes associated with LTOT, thereby preserving analgesic efficacy and improving long-term functional outcomes. Multiple formulations and flexible dosing options support personalized care, although regulatory restrictions and clinician unfamiliarity remain significant barriers. Buprenorphine is a viable yet underutilized option for managing CP, particularly when LTOT is anticipated. Broader clinical integration will require more precise guideline recommendations, clinician education, and policy reform. A paradigm shift toward early and proactive buprenorphine use could significantly improve safety, function, and quality of life in oncology patients.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7132","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:47:57Z","timestamp":1781527677000},"source":"Crossref","is-referenced-by-count":0,"title":["Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use"],"prefix":"10.6004","volume":"24","author":[{"given":"Marcin","family":"Chwistek","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Fox Chase Cancer Center\/Temple University Health, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Kinczewski","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Fox Chase Cancer Center\/Temple University Health, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin","family":"Buga","sequence":"additional","affiliation":[{"name":"Department of Supportive Care Medicine, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia L.","family":"Agne","sequence":"additional","affiliation":[{"name":"Division of Palliative Medicine, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Moryl","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center\/Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas","family":"Kandil","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Gupta","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center\/Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Anitescu","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Critical Care Medicine, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Javed","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Noonan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Fox Chase Cancer Center\/Temple University Health, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Sherry","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Fox Chase Cancer Center\/Temple University Health, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Pain Symptom Manage","first-page":"1070","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"van den Beuken-van Everdingen MHJ","year":"2016","unstructured":"van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten  EAJ,  Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 2016;51:1070\u20131090.e9."},{"key":"B2","series-title":"JAMA Oncol","first-page":"1224","article-title":"Prevalence of chronic pain and high-impact chronic pain in cancer survivors in the United States","volume":"5","author":"Jiang C","year":"2019","unstructured":"Jiang C, Wang H, Wang Q,  Prevalence of chronic pain and high-impact chronic pain in cancer survivors in the United States. JAMA Oncol 2019;5:1224\u20131226."},{"key":"B3","series-title":"Ann Oncol","first-page":"iv166","article-title":"Management of cancer pain in adult patients: ESMO clinical practice guidelines","volume":"29","author":"Fallon M","year":"2018","unstructured":"Fallon M, Giusti R, Aielli F,  Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol 2018;29:iv166\u2013191."},{"key":"B4","series-title":"J Natl Cancer Inst","first-page":"1476","article-title":"Estimation of the number of individuals living with metastatic cancer in the United States","volume":"114","author":"Gallicchio L","year":"2022","unstructured":"Gallicchio L, Devasia TP, Tonorezos E,  Estimation of the number of individuals living with metastatic cancer in the United States. J Natl Cancer Inst 2022;114:1476\u20131483."},{"key":"B5","series-title":"J Pain Symptom Manage","first-page":"395","article-title":"Exploring factors associated with long-term opioid therapy in cancer survivors: an integrative review","volume":"61","author":"Jones KF","year":"2021","unstructured":"Jones KF, Fu MR, Merlin JS,  Exploring factors associated with long-term opioid therapy in cancer survivors: an integrative review. J Pain Symptom Manage 2021;61:395\u2013415."},{"key":"B6","series-title":"J Clin Oncol","first-page":"3325","article-title":"Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"34","author":"Paice JA","year":"2016","unstructured":"Paice JA, Portenoy R, Lacchetti C,  Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016;34:3325\u20133345."},{"key":"B7","series-title":"JAMA Oncol","first-page":"1323","article-title":"Bridging the critical divide in pain management guidelines from the CDC, NCCN, and ASCO for cancer survivors","volume":"4","author":"Meghani SH","year":"2018","unstructured":"Meghani SH, Vapiwala N. Bridging the critical divide in pain management guidelines from the CDC, NCCN, and ASCO for cancer survivors. JAMA Oncol 2018;4:1323\u20131324."},{"key":"B8","series-title":"Oncologist","first-page":"567","article-title":"Chronic pain following treatment for cancer: the role of opioids","volume":"8","author":"Ballantyne JC","year":"2003","unstructured":"Ballantyne JC. Chronic pain following treatment for cancer: the role of opioids. Oncologist 2003;8:567\u2013575."},{"key":"B9","series-title":"Curr Treat Options Oncol","first-page":"116","article-title":"Treating chronic pain with buprenorphine\u2014the practical guide","volume":"22","author":"Case AA","year":"2021","unstructured":"Case AA, Kullgren J, Anwar S,  Treating chronic pain with buprenorphine\u2014the practical guide. Curr Treat Options Oncol 2021;22:116."},{"key":"B10","series-title":"Drugs R D","first-page":"339","article-title":"A guide to expanding the use of buprenorphine beyond standard initiations for opioid use disorder","volume":"23","author":"Miller JC","year":"2023","unstructured":"Miller JC, Brooks MA, Wurzel KE,  A guide to expanding the use of buprenorphine beyond standard initiations for opioid use disorder. Drugs R D 2023;23:339\u2013362."},{"key":"B11","series-title":"Front Biosci","first-page":"1291","article-title":"Buprenorphine in long-term control of chronic pain in cancer patients","volume":"12","author":"Pace M","year":"2007","unstructured":"Pace M, Passavanti M, Grella E,  Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci 2007;12:1291\u20131299."},{"key":"B12","series-title":"Ann Oncol","first-page":"1107","article-title":"Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u201creal-life\u201d trial on the variability of response to opioids","volume":"27","author":"Corli O","year":"2016","unstructured":"Corli O, Floriani I, Roberto A,  Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u201creal-life\u201d trial on the variability of response to opioids. Ann Oncol 2016;27:1107\u20131115."},{"key":"B13","series-title":"JAMA Oncol","first-page":"825","article-title":"Buprenorphine for cancer pain\u2013the safest opioid, and patients with cancer cannot get it","volume":"11","author":"Case AA","year":"2025","unstructured":"Case AA, Davis MP, Chwistek M, Zarrabi AJ. Buprenorphine for cancer pain\u2013the safest opioid, and patients with cancer cannot get it. JAMA Oncol 2025;11:825\u2013826."},{"key":"B14","series-title":"F1000Res","first-page":"945","article-title":"Recent advances in understanding and managing cancer pain","volume":"6","author":"Chwistek M","year":"2017","unstructured":"Chwistek M. Recent advances in understanding and managing cancer pain. F1000Res 2017;6:945."},{"key":"B15","series-title":"Pain","first-page":"1003","article-title":"A classification of chronic pain for ICD-11","volume":"156","author":"Treede RD","year":"2015","unstructured":"Treede RD, Rief W, Barke A,  A classification of chronic pain for ICD-11. Pain 2015;156:1003\u20131007."},{"key":"B16","series-title":"Cochrane Database Syst Rev","first-page":"CD012592","article-title":"Opioids for cancer pain \u2013 an overview of Cochrane reviews","volume":"7","author":"Wiffen PJ","year":"2017","unstructured":"Wiffen PJ, Wee B, Derry S,  Opioids for cancer pain \u2013 an overview of Cochrane reviews. Cochrane Database Syst Rev 2017;7:CD012592."},{"key":"B17","series-title":"Lancet Oncol","first-page":"e58","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni A","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S,  Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58\u201368."},{"key":"B18","series-title":"Curr Treat Options Oncol","first-page":"921","article-title":"Complex persistent opioid dependence\u2013an opioid-induced chronic pain syndrome","volume":"23","author":"Manhapra A","year":"2022","unstructured":"Manhapra A. Complex persistent opioid dependence\u2013an opioid-induced chronic pain syndrome. Curr Treat Options Oncol 2022;23:921\u2013935."},{"key":"B19","series-title":"J Clin Med","first-page":"1594","article-title":"Prevalence of opioid use disorder among patients with cancer-related pain: a systematic review","volume":"11","author":"Preux C","year":"2022","unstructured":"Preux C, Bertin M, Tarot A,  Prevalence of opioid use disorder among patients with cancer-related pain: a systematic review. J Clin Med 2022;11:1594."},{"key":"B20","series-title":"JAMA","first-page":"411","article-title":"Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids","volume":"326","author":"Agnoli A","year":"2021","unstructured":"Agnoli A, Xing G, Tancredi DJ,  Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA 2021;326:411\u2013419."},{"key":"B21","series-title":"J Pain","first-page":"958","article-title":"Arguments for and against a new diagnostic entity for patients with chronic pain on long-term opioid therapy for whom harms outweigh benefits","volume":"23","author":"Edmond SN","year":"2022","unstructured":"Edmond SN, Snow JL, Pomeranz J,  Arguments for and against a new diagnostic entity for patients with chronic pain on long-term opioid therapy for whom harms outweigh benefits. J Pain 2022;23:958\u2013966."},{"key":"B22","series-title":"Biol Psychiatry","first-page":"44","article-title":"Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement","volume":"87","author":"Koob GF","year":"2020","unstructured":"Koob GF. Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry 2020;87:44\u201353."},{"key":"B23","series-title":"Pain Med","first-page":"1092","article-title":"Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain","volume":"11","author":"Shurman J","year":"2010","unstructured":"Shurman J, Koob GF, Gutstein HB. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med 2010;11:1092\u20131098."},{"key":"B24","series-title":"Pain Med","first-page":"9","article-title":"Opioid-related endocrinopathy","volume":"16","author":"Gudin JA","year":"2015","unstructured":"Gudin JA, Laitman A, Nalamachu S. Opioid-related endocrinopathy. Pain Med 2015;16(Suppl 1):S9\u201315."},{"key":"B25","series-title":"Clin J Pain","first-page":"374","article-title":"Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment","volume":"26","author":"Rhodin A","year":"2010","unstructured":"Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010;26:374\u2013380."},{"key":"B26","series-title":"J Clin Endocrinol Metab","first-page":"2215","article-title":"Endocrine consequences of long-term intrathecal administration of opioids","volume":"85","author":"Abs R","year":"2000","unstructured":"Abs R, Verhelst J, Maeyaert J,  Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85:2215\u20132222."},{"key":"B27","series-title":"Cancer","first-page":"851","article-title":"Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids","volume":"100","author":"Rajagopal A","year":"2004","unstructured":"Rajagopal A, Vassilopoulou-Sellin R, Palmer JL,  Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100:851\u2013858."},{"key":"B28","series-title":"BMC Cancer","first-page":"127","article-title":"Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis","volume":"23","author":"Luo L","year":"2023","unstructured":"Luo L, Shen X, Fang S,  Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis. BMC Cancer 2023;23:127."},{"key":"B29","series-title":"Am J Ther","first-page":"354","article-title":"Opioid therapy and immunosuppression: a review","volume":"11","author":"Vallejo R","year":"2004","unstructured":"Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004;11:354\u2013365."},{"key":"B30","series-title":"J Biol Chem","first-page":"7164","article-title":"Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine","volume":"282","author":"Wang J","year":"2007","unstructured":"Wang J, Barke RA, Roy S. Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine. J Biol Chem 2007;282:7164\u20137171."},{"key":"B31","series-title":"Palliat Med","first-page":"s9","article-title":"Opioids and the immune system","volume":"20","author":"Sacerdote P","year":"2006","unstructured":"Sacerdote P. Opioids and the immune system. Palliat Med 2006;20 (Suppl 1):s9\u201315."},{"key":"B32","series-title":"Mol Pharmacol","first-page":"445","article-title":"Bidirectional relationship between opioids and disrupted sleep: putative mechanisms","volume":"98","author":"Eacret D","year":"2020","unstructured":"Eacret D, Veasey SC, Blendy JA. Bidirectional relationship between opioids and disrupted sleep: putative mechanisms. Mol Pharmacol 2020;98:445\u2013453."},{"key":"B33","series-title":"J Pain Symptom Manage","first-page":"200","article-title":"Effects of opioids on driving ability","volume":"19","author":"Galski T","year":"2000","unstructured":"Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage 2000;19:200\u2013208."},{"key":"B34","series-title":"Palliat Med","first-page":"109","article-title":"How to use opioid analgesics effectively and safely. Individual choice of the opioid in patients with cancer pain from the perspective of 2022","volume":"14","author":"Kotlinska-Lemieszek A","year":"2022","unstructured":"Kotlinska-Lemieszek A. How to use opioid analgesics effectively and safely. Individual choice of the opioid in patients with cancer pain from the perspective of 2022. Palliat Med 2022;14:109\u2013124."},{"key":"B35","series-title":"Pain","first-page":"870","article-title":"Delphi study to explore a new diagnosis for \u201cineffective\u201d long-term opioid therapy for chronic pain","volume":"164","author":"Edmond SN","year":"2023","unstructured":"Edmond SN, Snow JL, Pomeranz J,  Delphi study to explore a new diagnosis for \u201cineffective\u201d long-term opioid therapy for chronic pain. Pain 2023;164:870\u2013876."},{"key":"B36","series-title":"Ann N Y Acad Sci","first-page":"124","article-title":"The history of the development of buprenorphine as an addiction therapeutic","volume":"1248","author":"Campbell ND","year":"2012","unstructured":"Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci 2012;1248: 124\u2013139."},{"key":"B37","series-title":"JAMA Intern Med","first-page":"497","article-title":"Integrating buprenorphine into chronic pain treatment \u2013 putting the choice in VOICE","volume":"185","author":"Incze MA","year":"2025","unstructured":"Incze MA, Anderson TS. Integrating buprenorphine into chronic pain treatment \u2013 putting the choice in VOICE. JAMA Intern Med 2025;185:497\u2013498."},{"key":"B38","series-title":"Br J Anaesth","first-page":"627","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan A","year":"2006","unstructured":"Dahan A, Yassen A, Romberg R,  Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627\u2013632."},{"key":"B39","series-title":"CNS Drugs","first-page":"617","article-title":"Current and future therapeutic options in pain management: multi-mechanistic opioids involving both MOR and NOP receptor activation","volume":"36","author":"Coluzzi F","year":"2022","unstructured":"Coluzzi F, Rullo L, Scerpa MS,  Current and future therapeutic options in pain management: multi-mechanistic opioids involving both MOR and NOP receptor activation. CNS Drugs 2022;36:617\u2013632."},{"key":"B40","series-title":"Drugs","first-page":"215","article-title":"Buprenorphine pharmacodynamics: a bridge to understanding buprenorphine clinical benefits","volume":"85","author":"Davis M","year":"2025","unstructured":"Davis M. Buprenorphine pharmacodynamics: a bridge to understanding buprenorphine clinical benefits. Drugs 2025;85:215\u2013230."},{"key":"B41","series-title":"Am J Med Sci","first-page":"675","article-title":"A review of the safety of buprenorphine in special populations","volume":"364","author":"Brandt C","year":"2022","unstructured":"Brandt C, Atkinson TJ. A review of the safety of buprenorphine in special populations. Am J Med Sci 2022;364:675\u2013684."},{"key":"B42","series-title":"Pain Pract","first-page":"287","article-title":"Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids","volume":"8","author":"Pergolizzi J","year":"2008","unstructured":"Pergolizzi J, B\u00f6ger RH, Budd K,  Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids. Pain Pract 2008;8:287\u2013313."},{"key":"B43","series-title":"Pain","first-page":"385","article-title":"Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses","volume":"110","author":"Martucci C","year":"2004","unstructured":"Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 2004;110:385\u2013392."},{"key":"B44","series-title":"Brain Behav Immun","first-page":"767","article-title":"Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity, and metastatic colonization in rats in comparison with morphine or fentanyl treatment","volume":"21","author":"Franchi S","year":"2007","unstructured":"Franchi S, Panerai AE, Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity, and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 2007;21:767\u2013774."},{"key":"B45","series-title":"Clin Immunol","first-page":"179","article-title":"No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters","volume":"109","author":"D\u2019Elia M","year":"2003","unstructured":"D\u2019Elia M, Patenaude J, Hamelin C,  No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters. Clin Immunol 2003;109:179\u2013187."},{"key":"B46","series-title":"Curr Opin Nephrol Hypertens","first-page":"671","article-title":"Pain management in patients with chronic kidney disease and end-stage kidney disease","volume":"29","author":"Roy PJ","year":"2020","unstructured":"Roy PJ, Weltman M, Dember LM,  Pain management in patients with chronic kidney disease and end-stage kidney disease. Curr Opin Nephrol Hypertens 2020;29:671\u2013680."},{"key":"B47","series-title":"Eur J Clin Pharmacol","first-page":"143","article-title":"Pharmacokinetics of transdermal buprenorphine patch in the elderly","volume":"69","author":"Al-Tawil N","year":"2013","unstructured":"Al-Tawil N, Odar-Cederl\u00f6f I, Berggren AC,  Pharmacokinetics of transdermal buprenorphine patch in the elderly. Eur J Clin Pharmacol 2013;69:143\u2013149."},{"key":"B48","series-title":"Expert Rev Clin Pharmacol","first-page":"1159","article-title":"A narrative review of buprenorphine in adult cancer pain","volume":"13","author":"Degnan M","year":"2020","unstructured":"Degnan M, Mousa SA. A narrative review of buprenorphine in adult cancer pain. Expert Rev Clin Pharmacol 2020;13:1159\u20131167."},{"key":"B49","series-title":"Ther Clin Risk Manag","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain: safety aspects","volume":"2","author":"Likar R","year":"2006","unstructured":"Likar R. Transdermal buprenorphine in the management of persistent pain: safety aspects. Ther Clin Risk Manag 2006;2:115\u2013125."},{"key":"B50","series-title":"J Pain Res","first-page":"1963","article-title":"Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review","volume":"10","author":"Ahn JS","year":"2017","unstructured":"Ahn JS, Lin J, Ogawa S,  Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J Pain Res 2017;10:1963\u20131972."},{"key":"B51","series-title":"J Pain Symptom Manage","first-page":"117","article-title":"Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain","volume":"36","author":"Poulain P","year":"2008","unstructured":"Poulain P, Denier W, Douma J,  Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage 2008;36:117\u2013125."},{"key":"B52","series-title":"Curr Med Res Opin","first-page":"833","article-title":"Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain","volume":"28","author":"Wolff RF","year":"2012","unstructured":"Wolff RF, Aune D, Truyers C,  Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin 2012;28:833\u2013845."},{"key":"B53","series-title":"Springerplus","first-page":"87","article-title":"A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain","volume":"3","author":"Naing C","year":"2014","unstructured":"Naing C, Yeoh P, Aung K. A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain. Springerplus 2014;3:87."},{"key":"B54","series-title":"Cochrane Database Syst Rev","first-page":"CD009596","article-title":"Buprenorphine for treating cancer pain","volume":"2015","author":"Schmidt-Hansen M","year":"2015","unstructured":"Schmidt-Hansen M, Bromham N, Taubert M,  Buprenorphine for treating cancer pain. Cochrane Database Syst Rev 2015;2015:CD009596."},{"key":"B55","series-title":"J Pain Symptom Manage","first-page":"e525","article-title":"The effectiveness and safety of buprenorphine in palliative care: a systematic review of randomized controlled trials, prospective and retrospective studies","volume":"71","author":"Jose V","year":"2026","unstructured":"Jose V, Thekkekara R, Stuckler D, Greminger A. The effectiveness and safety of buprenorphine in palliative care: a systematic review of randomized controlled trials, prospective and retrospective studies. J Pain Symptom Manage 2026;71:e525\u2013539."},{"key":"B56","series-title":"J Opioid Manag","first-page":"85","article-title":"Transdermal opioids for cancer pain control in patients with renal impairment","volume":"10","author":"Melilli G","year":"2014","unstructured":"Melilli G, Samolsky Dekel BG, Frenquelli C,  Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag 2014;10:85\u201393."},{"key":"B57","article-title":"Buprenorphine transdermal system. Prescribing information","year":"2019","unstructured":"Buprenorphine transdermal system. Prescribing information. Purdue Pharma LP; 2019. Accessed April 14, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021306s035lbl.pdf"},{"key":"B58","series-title":"Ann Intern Med","first-page":"388","article-title":"The use of opioids in the management of chronic pain: synopsis of the 2022 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline","volume":"176","author":"Sandbrink F","year":"2023","unstructured":"Sandbrink F, Murphy JL, Johansson M,  The use of opioids in the management of chronic pain: synopsis of the 2022 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med 2023;176:388\u2013397."},{"key":"B59","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2013 United States,","volume":"71","author":"Dowell D","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM,  CDC clinical practice guideline for prescribing opioids for pain \u2013 United States, 2022. MMWR Recomm Rep 2022;71:1\u201395."},{"key":"B60","series-title":"CA Cancer J Clin","first-page":"286","article-title":"Opioid analgesics for nociceptive cancer pain: a comprehensive review","volume":"74","author":"Abdel Shaheed C","year":"2024","unstructured":"Abdel Shaheed C, Hayes C, Maher CG,  Opioid analgesics for nociceptive cancer pain: a comprehensive review. CA Cancer J Clin 2024;74:286\u2013313."},{"key":"B61","series-title":"J Pain Symptom Manage","first-page":"223","article-title":"Shifting views on cancer pain management: a systematic review and network meta-analysis","volume":"68","author":"Imkamp MSV","year":"2024","unstructured":"Imkamp MSV, Theunissen M, Viechtbauer W,  Shifting views on cancer pain management: a systematic review and network meta-analysis. J Pain Symptom Manage 2024;68:223\u2013236."},{"key":"B62","series-title":"J Natl Compr Canc Netw","first-page":"992","article-title":"Adult cancer pain","volume":"11","author":"Swarm RA","year":"2013","unstructured":"Swarm RA, Abernethy AP, Anghelescu DL,  Adult cancer pain. J Natl Compr Canc Netw 2013;11:992\u20131022."},{"key":"B63","article-title":"NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain","author":"Swarm RA","year":"2025","unstructured":"Swarm RA, Youngwerth JM, Agne JL,  NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain. Version 2.2025. Accessed November 20, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B64","article-title":"WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents.","year":"2025","unstructured":"World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Accessed March 31, 2025. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789241550390"},{"key":"B65","article-title":"The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th List","year":"2025","unstructured":"World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th List. Accessed September 11, 2025. Available at: https:\/\/www.who.int\/publications\/i\/item\/B09474"},{"key":"B66","article-title":"Palliative care pain and symptom control guidelines for adults","year":"2025","unstructured":"Greater Manchester Health and Social Care Partnership. Palliative care pain and symptom control guidelines for adults. Accessed March 31, 2025. Available at: https:\/\/www.england.nhs.uk\/north-west\/wp-content\/uploads\/sites\/48\/2020\/01\/Palliative-Care-Pain-and-Symptom-Control-Guidelines.pdf"},{"key":"B67","article-title":"guidelines on converting doses of opioid analgesics for adult use 2023","unstructured":"Health and Social Care in Northern Ireland. Northern Ireland guidelines on converting doses of opioid analgesics for adult use 2023. Accessed March 31, 2025. Available at: https:\/\/bso.hscni.net\/wp-content\/uploads\/2023\/10\/Opioid-Equivalence-Guidance-2023.pdf"},{"key":"B68","article-title":"Scottish palliative care guidelines","unstructured":"Healthcare Improvement Scotland. Scottish palliative care guidelines. Accessed March 31, 2025. Available at: https:\/\/www.palliativecareguidelines.scot.nhs.uk\/"},{"key":"B69","series-title":"Clin Transl Oncol","first-page":"97","article-title":"SEOM clinical guideline for treatment of cancer pain","volume":"20","author":"Jara C","year":"2018","unstructured":"Jara C, Del Barco S, Gr\u00e1valos C,  SEOM clinical guideline for treatment of cancer pain. Clin Transl Oncol 2018;20:97\u2013107."},{"key":"B70","article-title":"Palliative care for patients with incurable cancer","year":"2025","unstructured":"German Guideline Programme in Oncology (GGPO). Palliative care for patients with incurable cancer. Accessed March 31, 2025. Available at: https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Palliativmedizin\/Version_2\/GGPO_Palliative_Care_ShortVersion_2.2.pdf"},{"key":"B71","article-title":"Pain","year":"2025","unstructured":"Canadian Cancer Society. Pain. Accessed March 31, 2025. Available at: https:\/\/cancer.ca\/en\/treatments\/side-effects\/pain"},{"key":"B72","article-title":"Opioid conversion ratios: guidance document","year":"2025","unstructured":"Safer Care Victoria. Opioid conversion ratios: guidance document. Accessed March 31, 2025. Available at: https:\/\/www.safercare.vic.gov.au\/sites\/default\/files\/2021-02\/GUIDANCE_Opioid%20Conversion%20FINAL_0.pdf"},{"key":"B73","series-title":"J Palliat Med","first-page":"1095","article-title":"Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese Society of Palliative Medicine","volume":"25","author":"Mawatari H","year":"2022","unstructured":"Mawatari H, Shinjo T, Morita T,  Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese Society of Palliative Medicine. J Palliat Med 2022;25:1095\u20131114."},{"key":"B74","series-title":"J Clin Oncol","first-page":"914","article-title":"Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline","volume":"41","author":"Paice JA","year":"2023","unstructured":"Paice JA, Bohlke K, Barton D,  Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol 2023;41:914\u2013930."},{"key":"B75","article-title":"Cancer pain: clinical practice guideline","year":"2025","unstructured":"Alberta Health Services. Cancer pain: clinical practice guideline. Accessed March 31, 2025. Available at: https:\/\/www.albertahealthservices.ca\/assets\/info\/hp\/cancer\/if-hp-cancer-guide-supp012-cancer-pain.pdf"},{"key":"B76","article-title":"Cancer pain management in adults clinical guidelines","year":"2025","unstructured":"Cancer Council Australia. Cancer pain management in adults clinical guidelines. Accessed March 31, 2025. Available at: https:\/\/www.cancer.org.au\/clinical-guidelines\/cancer-pain-management"},{"key":"B77","article-title":"Palliative care for the patient with incurable cancer or advanced disease \u2013 part 2: pain and symptom management","year":"2025","unstructured":"Medical Services Commission of British Columbia, Guidelines and Protocols Advisory Committee. Palliative care for the patient with incurable cancer or advanced disease \u2013 part 2: pain and symptom management. Accessed March 31, 2025. Available at: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/bc-guidelines\/palliative-pain-management"},{"key":"B78","series-title":"J Support Oncol","first-page":"209","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis MP","year":"2012","unstructured":"Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012;10:209\u2013219."},{"key":"B79","series-title":"J Opioid Manag","first-page":"285","article-title":"Patients\u2019 perceptions of buprenorphine use receiving treatment for cancer","volume":"19","author":"Yeung A","year":"2023","unstructured":"Yeung A, Galvez-Peralta M, Apopa J,  Patients\u2019 perceptions of buprenorphine use receiving treatment for cancer. J Opioid Manag 2023;19:285\u2013289."},{"key":"B80","series-title":"J Pain Symptom Manage","first-page":"119","article-title":"Barriers to buprenorphine prescribing for opioid use disorder in hospice and palliative care","volume":"64","author":"Ho JJ","year":"2022","unstructured":"Ho JJ, Jones KF, Sager Z,  Barriers to buprenorphine prescribing for opioid use disorder in hospice and palliative care. J Pain Symptom Manage 2022;64:119\u2013127."},{"key":"B81","article-title":"Cancer pain (adults): pharmacological management (clinical guideline 140)","year":"2025","unstructured":"National Institute for Health and Care Excellence (NICE). Cancer pain (adults): pharmacological management (clinical guideline 140). Accessed March 31,02025. Available at: https:\/\/www.nice.org.uk\/guidance\/cg140"},{"key":"B82","series-title":"Ann Med Surg (Lond)","first-page":"44","article-title":"NICE opioids in palliative care (clinical guideline 140) \u2013 a guideline summary","volume":"1","author":"Teoh PJ","year":"2012","unstructured":"Teoh PJ, Camm CF. NICE opioids in palliative care (clinical guideline 140) \u2013 a guideline summary. Ann Med Surg (Lond) 2012;1:44\u201348."},{"key":"B83","series-title":"Clin Pharmacol Ther","first-page":"569","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh SL","year":"1994","unstructured":"Walsh SL, Preston KL, Stitzer ML,  Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569\u2013580."},{"key":"B84","series-title":"Clin Ther","first-page":"225","article-title":"Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study","volume":"27","author":"Sittl R","year":"2005","unstructured":"Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 2005;27:225\u2013237."},{"key":"B85","series-title":"Palliat Med","first-page":"504","article-title":"Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review","volume":"25","author":"Mercadante S","year":"2011","unstructured":"Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011;25:504\u2013515."},{"key":"B86","series-title":"J Pain Symptom Manage","first-page":"e141","article-title":"Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline clinical insights","volume":"71","author":"Davis MP","year":"2026","unstructured":"Davis MP, Bohlke K, Davies A. Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline clinical insights. J Pain Symptom Manage 2026;71:e141\u2013144."},{"key":"B87","series-title":"Pain Med","first-page":"1109","article-title":"Conversion of schedule II opioids to buprenorphine buccal film: a retrospective analysis","volume":"22","author":"Zimmerman A","year":"2021","unstructured":"Zimmerman A, Bikdash R, Rauck R. Conversion of schedule II opioids to buprenorphine buccal film: a retrospective analysis. Pain Med 2021;22:1109\u20131115."},{"key":"B88","series-title":"Drug Alcohol Depend","first-page":"109013","article-title":"Analysis of genetic and clinical factors associated with buprenorphine response","volume":"227","author":"Crist RC","year":"2021","unstructured":"Crist RC, Vickers-Smith R, Kember RL,  Analysis of genetic and clinical factors associated with buprenorphine response. Drug Alcohol Depend 2021;227:109013."},{"key":"B89","series-title":"Int J Neuropsychopharmacol","first-page":"89","article-title":"A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder","volume":"24","author":"Kranzler HR","year":"2021","unstructured":"Kranzler HR, Lynch KG, Crist RC,  A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder. Int J Neuropsychopharmacol 2021;24:89\u201396."},{"key":"B90","article-title":"Buprenorphine buccal film. Prescribing information. Collegium Pharmaceuticals","year":"2023","unstructured":"Buprenorphine buccal film. Prescribing information. Collegium Pharmaceuticals; 2023. Accessed March 28, 2025. Available at: https:\/\/www.belbuca.com\/pdfs\/belbuca-prescribing-info.pdf"},{"key":"B91","series-title":"J Am Dent Assoc","first-page":"561","article-title":"Orally dissolving buprenorphine for opioid use disorder linked to caries","volume":"155","author":"Segelnick SL","year":"2024","unstructured":"Segelnick SL, Weinberg MA. Orally dissolving buprenorphine for opioid use disorder linked to caries. J Am Dent Assoc 2024;155:561\u2013564."},{"key":"B92","series-title":"Curr Drug Saf","first-page":"261","article-title":"Dental disorders reported to the FDA adverse event reporting system in association with buprenorphine: an analysis by ingredient composition and route of administration","volume":"19","author":"Woods RH","year":"2024","unstructured":"Woods RH. Dental disorders reported to the FDA adverse event reporting system in association with buprenorphine: an analysis by ingredient composition and route of administration. Curr Drug Saf 2024;19:261\u2013267."},{"key":"B93","series-title":"Clin Ther","first-page":"299","article-title":"Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy","volume":"20","author":"Wilson DE","year":"1998","unstructured":"Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998;20:299\u2013306."},{"key":"B94","article-title":"Buprenorphine for pain management: pros vs cons in the hospice population","year":"2025","unstructured":"ProCare HospiceCare. Buprenorphine for pain management: pros vs cons in the hospice population. Accessed September 11, 2025. Available at: https:\/\/www.procarehospicecare.com\/buprenorphine-for-pain-management-pros-vs-cons-in-the-hospice-population"},{"key":"B95","series-title":"J Pain Symptom Manage","first-page":"e582","article-title":"Assessing provider barriers to use of buprenorphine for cancer-related pain","volume":"69","author":"Rahman I","year":"2025","unstructured":"Rahman I, AuBuchon K, McElreath K,  Assessing provider barriers to use of buprenorphine for cancer-related pain. J Pain Symptom Manage 2025;69:e582\u2013583."},{"key":"B96","series-title":"J Pain Symptom Manage","first-page":"e330","article-title":"Providers' barriers to buprenorphine prescribing for cancer-related pain","volume":"69","author":"AuBuchon KE","year":"2025","unstructured":"AuBuchon KE, Boanca KM, Muthineni N,  Providers' barriers to buprenorphine prescribing for cancer-related pain. J Pain Symptom Manage 2025;69:e330\u2013336."},{"key":"B97","series-title":"JAMA Intern Med","first-page":"372","article-title":"Buprenorphine, pain, and opioid use in patients taking high-dose long-term opioids: a randomized clinical trial","volume":"185","author":"Becker WC","year":"2025","unstructured":"Becker WC, Seal KH, Nelson DB,  Buprenorphine, pain, and opioid use in patients taking high-dose long-term opioids: a randomized clinical trial. JAMA Intern Med 2025;185:372\u2013381."},{"key":"B98","series-title":"Transl Psychiatry","first-page":"20","article-title":"Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records","volume":"14","author":"Niarchou M","year":"2024","unstructured":"Niarchou M, Sanchez-Roige S, Reddy IA,  Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records. Transl Psychiatry 2024;14:20."},{"key":"B99","series-title":"J Pain Symptom Manage","first-page":"e138","article-title":"Creating a palliative care clinic for patients with cancer pain and substance use disorder","volume":"68","author":"Kale SS","year":"2024","unstructured":"Kale SS, Tosto GD, Rush LJ,  Creating a palliative care clinic for patients with cancer pain and substance use disorder. J Pain Symptom Manage 2024;68:e138\u2013145."},{"key":"B100","series-title":"J Am Pharm Assoc (2003)","first-page":"102319","article-title":"Community pharmacy-based buprenorphine programs and pharmacists\u2019 roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: a systematic review","volume":"65","author":"Rawal S","year":"2025","unstructured":"Rawal S, Welsh JW, Yarbrough CR,  Community pharmacy-based buprenorphine programs and pharmacists\u2019 roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: a systematic review. J Am Pharm Assoc (2003) 2025;65:102319."},{"key":"B101","series-title":"J Am Pharm Assoc (2003)","first-page":"1606","article-title":"North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter D","year":"2022","unstructured":"Carpenter D, Lambert KV, Harless JC,  North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes. J Am Pharm Assoc (2003) 2022;62:1606\u20131614."},{"key":"B102","series-title":"Pain Med","first-page":"S19","article-title":"Patient experiences navigating chronic pain management in an integrated health care system: a qualitative investigation of women and men","volume":"19","author":"Driscoll MA","year":"2018","unstructured":"Driscoll MA, Knobf MT, Higgins DM,  Patient experiences navigating chronic pain management in an integrated health care system: a qualitative investigation of women and men. Pain Med 2018;19(Suppl 1):S19\u201329."},{"key":"B103","series-title":"N Engl J Med","first-page":"703","article-title":"When prescribing isn't enough \u2013 pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper HLF","year":"2020","unstructured":"Cooper HLF, Cloud DH, Young AM, Freeman PR. When prescribing isn't enough \u2013 pharmacy-level barriers to buprenorphine access. N Engl J Med 2020;383:703\u2013705."},{"key":"B104","series-title":"Int J Drug Policy","first-page":"102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper HL","year":"2020","unstructured":"Cooper HL, Cloud DH, Freeman PR,  Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy 2020;85:102701."},{"key":"B105","series-title":"J Addict Med","first-page":"68","article-title":"A brief online training to address pharmacists\u2019 willingness to dispense buprenorphine","volume":"18","author":"Carpenter D","year":"2024","unstructured":"Carpenter D, Mashburn P, Viracola C,  A brief online training to address pharmacists\u2019 willingness to dispense buprenorphine. J Addict Med 2024;18:68\u201370."},{"key":"B106","series-title":"Support Care Cancer","first-page":"1","article-title":"Abstracts for MASCC\/ISOO Annual Meeting 2022","volume":"30","author":"Davis M","year":"2022","unstructured":"Davis M, Maybach A, Teoli D. Abstracts for MASCC\/ISOO Annual Meeting 2022. Support Care Cancer 2022;30(Suppl 1):1\u2013207."},{"key":"B107","series-title":"Blood","first-page":"2568","article-title":"\u201cBuprenorphine, it works so differently\u201d: adults with sickle cell disease describe their experiences transitioning to buprenorphine for treatment of chronic pain","volume":"140","author":"Loeser PC","year":"2022","unstructured":"Loeser PC, Early ML, Carroll CP,  \u201cBuprenorphine, it works so differently\u201d: adults with sickle cell disease describe their experiences transitioning to buprenorphine for treatment of chronic pain. Blood 2022;140(Suppl 1):2568\u20132569."},{"key":"B108","series-title":"Anesth Analg","first-page":"1779","article-title":"Case series of successful postoperative pain management in buprenorphine maintenance therapy patients","volume":"125","author":"Leighton BL","year":"2017","unstructured":"Leighton BL, Crock LW. Case series of successful postoperative pain management in buprenorphine maintenance therapy patients. Anesth Analg 2017;125:1779\u20131783."},{"key":"B109","series-title":"Pain Med","first-page":"714","article-title":"Understanding buprenorphine for use in chronic pain: expert opinion","volume":"21","author":"Webster L","year":"2020","unstructured":"Webster L, Gudin J, Raffa RB,  Understanding buprenorphine for use in chronic pain: expert opinion. Pain Med 2020;21:714\u2013723."},{"key":"B110","series-title":"Pain","first-page":"309","article-title":"Opioid-induced constipation in patients with cancer: a \u201creal-world,\u201d multicentre, observational study of diagnostic criteria and clinical features","volume":"162","author":"Davies A","year":"2021","unstructured":"Davies A, Leach C, Butler C,  Opioid-induced constipation in patients with cancer: a \u201creal-world,\u201d multicentre, observational study of diagnostic criteria and clinical features. Pain 2021;162:309\u2013318."},{"key":"B111","series-title":"J Opioid Manag","first-page":"543","article-title":"Outpatient cross-titration to buprenorphine for chronic pain: a retrospective analysis","volume":"19","author":"Ito S","year":"2023","unstructured":"Ito S, Welsh M, Bockman C,  Outpatient cross-titration to buprenorphine for chronic pain: a retrospective analysis. J Opioid Manag 2023;19:543\u2013554."},{"key":"B112","series-title":"JAMA Netw Open","first-page":"e2124152","article-title":"Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review","volume":"4","author":"Powell VD","year":"2021","unstructured":"Powell VD, Rosenberg JM, Yaganti A,  Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review. JAMA Netw Open 2021;4:e2124152."},{"key":"B113","series-title":"Pharmacoepidemiol Drug Saf","first-page":"733","article-title":"A synthesis of oral morphine equivalents (OME) for opioid utilisation studies","volume":"25","author":"Nielsen S","year":"2016","unstructured":"Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf 2016;25:733\u2013737."},{"key":"B114","series-title":"Pain Pract","first-page":"123","article-title":"Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients","volume":"7","author":"Freye E","year":"2007","unstructured":"Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract 2007;7:123\u2013129."},{"key":"B115","series-title":"Pain Med","first-page":"899","article-title":"Evaluation of the tolerability of switching patients on chronic full \u03bc-opioid agonist therapy to buccal buprenorphine","volume":"17","author":"Webster L","year":"2016","unstructured":"Webster L, Gruener D, Kirby T,  Evaluation of the tolerability of switching patients on chronic full \u03bc-opioid agonist therapy to buccal buprenorphine. Pain Med 2016;17:899\u2013907."},{"key":"B116","series-title":"Ann Intern Med","first-page":"70","article-title":"Switching from high-dose, long-term opioids to buprenorphine: a case series","volume":"173","author":"Becker WC","year":"2020","unstructured":"Becker WC, Frank JW, Edens EL. Switching from high-dose, long-term opioids to buprenorphine: a case series. Ann Intern Med 2020;173:70\u201371."},{"key":"B117","series-title":"J Palliat Med","first-page":"145","article-title":"Buprenorphine microdosing for the pain and palliative care clinician","volume":"25","author":"Quirk K","year":"2022","unstructured":"Quirk K, Stevenson M. Buprenorphine microdosing for the pain and palliative care clinician. J Palliat Med 2022;25:145\u2013154."},{"key":"B118","series-title":"Can J Pain","first-page":"2310811","article-title":"Low-dose initiation of buprenorphine\/naloxone for the management of chronic noncancer pain in patients on long-term opioid therapy: a case series","volume":"8","author":"Rattanavong M","year":"2024","unstructured":"Rattanavong M, Kwan D, Jorgenson D,  Low-dose initiation of buprenorphine\/naloxone for the management of chronic noncancer pain in patients on long-term opioid therapy: a case series. Can J Pain 2024;8:2310811."},{"key":"B119","series-title":"Curr Med Res Opin","first-page":"1517","article-title":"The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus","volume":"25","author":"Pergolizzi JV","year":"2009","unstructured":"Pergolizzi JV, Mercadante S, Echaburu AV,  The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517\u20131528."},{"key":"B120","series-title":"PLoS One","first-page":"e0241362","article-title":"Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block","volume":"15","author":"Tran PN","year":"2020","unstructured":"Tran PN, Sheng J, Randolph AL,  Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. PLoS One 2020;15:e0241362."},{"key":"B121","series-title":"Arch Intern Med","first-page":"2469","article-title":"QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial","volume":"167","author":"Wedam EF","year":"2007","unstructured":"Wedam EF, Bigelow GE, Johnson RE,  QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167:2469\u20132475."},{"key":"B1","series-title":"J Pain Symptom Manage","first-page":"1070","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"van den Beuken-van Everdingen MHJ","year":"2016","unstructured":"van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten  EAJ,  Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 2016;51:1070\u20131090.e9."},{"key":"B2","series-title":"JAMA Oncol","first-page":"1224","article-title":"Prevalence of chronic pain and high-impact chronic pain in cancer survivors in the United States","volume":"5","author":"Jiang C","year":"2019","unstructured":"Jiang C, Wang H, Wang Q,  Prevalence of chronic pain and high-impact chronic pain in cancer survivors in the United States. JAMA Oncol 2019;5:1224\u20131226."},{"key":"B3","series-title":"Ann Oncol","first-page":"iv166","article-title":"Management of cancer pain in adult patients: ESMO clinical practice guidelines","volume":"29","author":"Fallon M","year":"2018","unstructured":"Fallon M, Giusti R, Aielli F,  Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol 2018;29:iv166\u2013191."},{"key":"B4","series-title":"J Natl Cancer Inst","first-page":"1476","article-title":"Estimation of the number of individuals living with metastatic cancer in the United States","volume":"114","author":"Gallicchio L","year":"2022","unstructured":"Gallicchio L, Devasia TP, Tonorezos E,  Estimation of the number of individuals living with metastatic cancer in the United States. J Natl Cancer Inst 2022;114:1476\u20131483."},{"key":"B5","series-title":"J Pain Symptom Manage","first-page":"395","article-title":"Exploring factors associated with long-term opioid therapy in cancer survivors: an integrative review","volume":"61","author":"Jones KF","year":"2021","unstructured":"Jones KF, Fu MR, Merlin JS,  Exploring factors associated with long-term opioid therapy in cancer survivors: an integrative review. J Pain Symptom Manage 2021;61:395\u2013415."},{"key":"B6","series-title":"J Clin Oncol","first-page":"3325","article-title":"Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"34","author":"Paice JA","year":"2016","unstructured":"Paice JA, Portenoy R, Lacchetti C,  Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016;34:3325\u20133345."},{"key":"B7","series-title":"JAMA Oncol","first-page":"1323","article-title":"Bridging the critical divide in pain management guidelines from the CDC, NCCN, and ASCO for cancer survivors","volume":"4","author":"Meghani SH","year":"2018","unstructured":"Meghani SH, Vapiwala N. Bridging the critical divide in pain management guidelines from the CDC, NCCN, and ASCO for cancer survivors. JAMA Oncol 2018;4:1323\u20131324."},{"key":"B8","series-title":"Oncologist","first-page":"567","article-title":"Chronic pain following treatment for cancer: the role of opioids","volume":"8","author":"Ballantyne JC","year":"2003","unstructured":"Ballantyne JC. Chronic pain following treatment for cancer: the role of opioids. Oncologist 2003;8:567\u2013575."},{"key":"B9","series-title":"Curr Treat Options Oncol","first-page":"116","article-title":"Treating chronic pain with buprenorphine\u2014the practical guide","volume":"22","author":"Case AA","year":"2021","unstructured":"Case AA, Kullgren J, Anwar S,  Treating chronic pain with buprenorphine\u2014the practical guide. Curr Treat Options Oncol 2021;22:116."},{"key":"B10","series-title":"Drugs R D","first-page":"339","article-title":"A guide to expanding the use of buprenorphine beyond standard initiations for opioid use disorder","volume":"23","author":"Miller JC","year":"2023","unstructured":"Miller JC, Brooks MA, Wurzel KE,  A guide to expanding the use of buprenorphine beyond standard initiations for opioid use disorder. Drugs R D 2023;23:339\u2013362."},{"key":"B11","series-title":"Front Biosci","first-page":"1291","article-title":"Buprenorphine in long-term control of chronic pain in cancer patients","volume":"12","author":"Pace M","year":"2007","unstructured":"Pace M, Passavanti M, Grella E,  Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci 2007;12:1291\u20131299."},{"key":"B12","series-title":"Ann Oncol","first-page":"1107","article-title":"Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u201creal-life\u201d trial on the variability of response to opioids","volume":"27","author":"Corli O","year":"2016","unstructured":"Corli O, Floriani I, Roberto A,  Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u201creal-life\u201d trial on the variability of response to opioids. Ann Oncol 2016;27:1107\u20131115."},{"key":"B13","series-title":"JAMA Oncol","first-page":"825","article-title":"Buprenorphine for cancer pain\u2013the safest opioid, and patients with cancer cannot get it","volume":"11","author":"Case AA","year":"2025","unstructured":"Case AA, Davis MP, Chwistek M, Zarrabi AJ. Buprenorphine for cancer pain\u2013the safest opioid, and patients with cancer cannot get it. JAMA Oncol 2025;11:825\u2013826."},{"key":"B14","series-title":"F1000Res","first-page":"945","article-title":"Recent advances in understanding and managing cancer pain","volume":"6","author":"Chwistek M","year":"2017","unstructured":"Chwistek M. Recent advances in understanding and managing cancer pain. F1000Res 2017;6:945."},{"key":"B15","series-title":"Pain","first-page":"1003","article-title":"A classification of chronic pain for ICD-11","volume":"156","author":"Treede RD","year":"2015","unstructured":"Treede RD, Rief W, Barke A,  A classification of chronic pain for ICD-11. Pain 2015;156:1003\u20131007."},{"key":"B16","series-title":"Cochrane Database Syst Rev","first-page":"CD012592","article-title":"Opioids for cancer pain \u2013 an overview of Cochrane reviews","volume":"7","author":"Wiffen PJ","year":"2017","unstructured":"Wiffen PJ, Wee B, Derry S,  Opioids for cancer pain \u2013 an overview of Cochrane reviews. Cochrane Database Syst Rev 2017;7:CD012592."},{"key":"B17","series-title":"Lancet Oncol","first-page":"e58","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni A","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S,  Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58\u201368."},{"key":"B18","series-title":"Curr Treat Options Oncol","first-page":"921","article-title":"Complex persistent opioid dependence\u2013an opioid-induced chronic pain syndrome","volume":"23","author":"Manhapra A","year":"2022","unstructured":"Manhapra A. Complex persistent opioid dependence\u2013an opioid-induced chronic pain syndrome. Curr Treat Options Oncol 2022;23:921\u2013935."},{"key":"B19","series-title":"J Clin Med","first-page":"1594","article-title":"Prevalence of opioid use disorder among patients with cancer-related pain: a systematic review","volume":"11","author":"Preux C","year":"2022","unstructured":"Preux C, Bertin M, Tarot A,  Prevalence of opioid use disorder among patients with cancer-related pain: a systematic review. J Clin Med 2022;11:1594."},{"key":"B20","series-title":"JAMA","first-page":"411","article-title":"Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids","volume":"326","author":"Agnoli A","year":"2021","unstructured":"Agnoli A, Xing G, Tancredi DJ,  Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA 2021;326:411\u2013419."},{"key":"B21","series-title":"J Pain","first-page":"958","article-title":"Arguments for and against a new diagnostic entity for patients with chronic pain on long-term opioid therapy for whom harms outweigh benefits","volume":"23","author":"Edmond SN","year":"2022","unstructured":"Edmond SN, Snow JL, Pomeranz J,  Arguments for and against a new diagnostic entity for patients with chronic pain on long-term opioid therapy for whom harms outweigh benefits. J Pain 2022;23:958\u2013966."},{"key":"B22","series-title":"Biol Psychiatry","first-page":"44","article-title":"Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement","volume":"87","author":"Koob GF","year":"2020","unstructured":"Koob GF. Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry 2020;87:44\u201353."},{"key":"B23","series-title":"Pain Med","first-page":"1092","article-title":"Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain","volume":"11","author":"Shurman J","year":"2010","unstructured":"Shurman J, Koob GF, Gutstein HB. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med 2010;11:1092\u20131098."},{"key":"B24","series-title":"Pain Med","first-page":"9","article-title":"Opioid-related endocrinopathy","volume":"16","author":"Gudin JA","year":"2015","unstructured":"Gudin JA, Laitman A, Nalamachu S. Opioid-related endocrinopathy. Pain Med 2015;16(Suppl 1):S9\u201315."},{"key":"B25","series-title":"Clin J Pain","first-page":"374","article-title":"Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment","volume":"26","author":"Rhodin A","year":"2010","unstructured":"Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010;26:374\u2013380."},{"key":"B26","series-title":"J Clin Endocrinol Metab","first-page":"2215","article-title":"Endocrine consequences of long-term intrathecal administration of opioids","volume":"85","author":"Abs R","year":"2000","unstructured":"Abs R, Verhelst J, Maeyaert J,  Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85:2215\u20132222."},{"key":"B27","series-title":"Cancer","first-page":"851","article-title":"Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids","volume":"100","author":"Rajagopal A","year":"2004","unstructured":"Rajagopal A, Vassilopoulou-Sellin R, Palmer JL,  Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100:851\u2013858."},{"key":"B28","series-title":"BMC Cancer","first-page":"127","article-title":"Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis","volume":"23","author":"Luo L","year":"2023","unstructured":"Luo L, Shen X, Fang S,  Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis. BMC Cancer 2023;23:127."},{"key":"B29","series-title":"Am J Ther","first-page":"354","article-title":"Opioid therapy and immunosuppression: a review","volume":"11","author":"Vallejo R","year":"2004","unstructured":"Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004;11:354\u2013365."},{"key":"B30","series-title":"J Biol Chem","first-page":"7164","article-title":"Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine","volume":"282","author":"Wang J","year":"2007","unstructured":"Wang J, Barke RA, Roy S. Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine. J Biol Chem 2007;282:7164\u20137171."},{"key":"B31","series-title":"Palliat Med","first-page":"s9","article-title":"Opioids and the immune system","volume":"20","author":"Sacerdote P","year":"2006","unstructured":"Sacerdote P. Opioids and the immune system. Palliat Med 2006;20 (Suppl 1):s9\u201315."},{"key":"B32","series-title":"Mol Pharmacol","first-page":"445","article-title":"Bidirectional relationship between opioids and disrupted sleep: putative mechanisms","volume":"98","author":"Eacret D","year":"2020","unstructured":"Eacret D, Veasey SC, Blendy JA. Bidirectional relationship between opioids and disrupted sleep: putative mechanisms. Mol Pharmacol 2020;98:445\u2013453."},{"key":"B33","series-title":"J Pain Symptom Manage","first-page":"200","article-title":"Effects of opioids on driving ability","volume":"19","author":"Galski T","year":"2000","unstructured":"Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage 2000;19:200\u2013208."},{"key":"B34","series-title":"Palliat Med","first-page":"109","article-title":"How to use opioid analgesics effectively and safely. Individual choice of the opioid in patients with cancer pain from the perspective of 2022","volume":"14","author":"Kotlinska-Lemieszek A","year":"2022","unstructured":"Kotlinska-Lemieszek A. How to use opioid analgesics effectively and safely. Individual choice of the opioid in patients with cancer pain from the perspective of 2022. Palliat Med 2022;14:109\u2013124."},{"key":"B35","series-title":"Pain","first-page":"870","article-title":"Delphi study to explore a new diagnosis for \u201cineffective\u201d long-term opioid therapy for chronic pain","volume":"164","author":"Edmond SN","year":"2023","unstructured":"Edmond SN, Snow JL, Pomeranz J,  Delphi study to explore a new diagnosis for \u201cineffective\u201d long-term opioid therapy for chronic pain. Pain 2023;164:870\u2013876."},{"key":"B36","series-title":"Ann N Y Acad Sci","first-page":"124","article-title":"The history of the development of buprenorphine as an addiction therapeutic","volume":"1248","author":"Campbell ND","year":"2012","unstructured":"Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci 2012;1248: 124\u2013139."},{"key":"B37","series-title":"JAMA Intern Med","first-page":"497","article-title":"Integrating buprenorphine into chronic pain treatment \u2013 putting the choice in VOICE","volume":"185","author":"Incze MA","year":"2025","unstructured":"Incze MA, Anderson TS. Integrating buprenorphine into chronic pain treatment \u2013 putting the choice in VOICE. JAMA Intern Med 2025;185:497\u2013498."},{"key":"B38","series-title":"Br J Anaesth","first-page":"627","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan A","year":"2006","unstructured":"Dahan A, Yassen A, Romberg R,  Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627\u2013632."},{"key":"B39","series-title":"CNS Drugs","first-page":"617","article-title":"Current and future therapeutic options in pain management: multi-mechanistic opioids involving both MOR and NOP receptor activation","volume":"36","author":"Coluzzi F","year":"2022","unstructured":"Coluzzi F, Rullo L, Scerpa MS,  Current and future therapeutic options in pain management: multi-mechanistic opioids involving both MOR and NOP receptor activation. CNS Drugs 2022;36:617\u2013632."},{"key":"B40","series-title":"Drugs","first-page":"215","article-title":"Buprenorphine pharmacodynamics: a bridge to understanding buprenorphine clinical benefits","volume":"85","author":"Davis M","year":"2025","unstructured":"Davis M. Buprenorphine pharmacodynamics: a bridge to understanding buprenorphine clinical benefits. Drugs 2025;85:215\u2013230."},{"key":"B41","series-title":"Am J Med Sci","first-page":"675","article-title":"A review of the safety of buprenorphine in special populations","volume":"364","author":"Brandt C","year":"2022","unstructured":"Brandt C, Atkinson TJ. A review of the safety of buprenorphine in special populations. Am J Med Sci 2022;364:675\u2013684."},{"key":"B42","series-title":"Pain Pract","first-page":"287","article-title":"Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids","volume":"8","author":"Pergolizzi J","year":"2008","unstructured":"Pergolizzi J, B\u00f6ger RH, Budd K,  Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids. Pain Pract 2008;8:287\u2013313."},{"key":"B43","series-title":"Pain","first-page":"385","article-title":"Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses","volume":"110","author":"Martucci C","year":"2004","unstructured":"Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 2004;110:385\u2013392."},{"key":"B44","series-title":"Brain Behav Immun","first-page":"767","article-title":"Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity, and metastatic colonization in rats in comparison with morphine or fentanyl treatment","volume":"21","author":"Franchi S","year":"2007","unstructured":"Franchi S, Panerai AE, Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity, and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 2007;21:767\u2013774."},{"key":"B45","series-title":"Clin Immunol","first-page":"179","article-title":"No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters","volume":"109","author":"D\u2019Elia M","year":"2003","unstructured":"D\u2019Elia M, Patenaude J, Hamelin C,  No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters. Clin Immunol 2003;109:179\u2013187."},{"key":"B46","series-title":"Curr Opin Nephrol Hypertens","first-page":"671","article-title":"Pain management in patients with chronic kidney disease and end-stage kidney disease","volume":"29","author":"Roy PJ","year":"2020","unstructured":"Roy PJ, Weltman M, Dember LM,  Pain management in patients with chronic kidney disease and end-stage kidney disease. Curr Opin Nephrol Hypertens 2020;29:671\u2013680."},{"key":"B47","series-title":"Eur J Clin Pharmacol","first-page":"143","article-title":"Pharmacokinetics of transdermal buprenorphine patch in the elderly","volume":"69","author":"Al-Tawil N","year":"2013","unstructured":"Al-Tawil N, Odar-Cederl\u00f6f I, Berggren AC,  Pharmacokinetics of transdermal buprenorphine patch in the elderly. Eur J Clin Pharmacol 2013;69:143\u2013149."},{"key":"B48","series-title":"Expert Rev Clin Pharmacol","first-page":"1159","article-title":"A narrative review of buprenorphine in adult cancer pain","volume":"13","author":"Degnan M","year":"2020","unstructured":"Degnan M, Mousa SA. A narrative review of buprenorphine in adult cancer pain. Expert Rev Clin Pharmacol 2020;13:1159\u20131167."},{"key":"B49","series-title":"Ther Clin Risk Manag","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain: safety aspects","volume":"2","author":"Likar R","year":"2006","unstructured":"Likar R. Transdermal buprenorphine in the management of persistent pain: safety aspects. Ther Clin Risk Manag 2006;2:115\u2013125."},{"key":"B50","series-title":"J Pain Res","first-page":"1963","article-title":"Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review","volume":"10","author":"Ahn JS","year":"2017","unstructured":"Ahn JS, Lin J, Ogawa S,  Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J Pain Res 2017;10:1963\u20131972."},{"key":"B51","series-title":"J Pain Symptom Manage","first-page":"117","article-title":"Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain","volume":"36","author":"Poulain P","year":"2008","unstructured":"Poulain P, Denier W, Douma J,  Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage 2008;36:117\u2013125."},{"key":"B52","series-title":"Curr Med Res Opin","first-page":"833","article-title":"Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain","volume":"28","author":"Wolff RF","year":"2012","unstructured":"Wolff RF, Aune D, Truyers C,  Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin 2012;28:833\u2013845."},{"key":"B53","series-title":"Springerplus","first-page":"87","article-title":"A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain","volume":"3","author":"Naing C","year":"2014","unstructured":"Naing C, Yeoh P, Aung K. A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain. Springerplus 2014;3:87."},{"key":"B54","series-title":"Cochrane Database Syst Rev","first-page":"CD009596","article-title":"Buprenorphine for treating cancer pain","volume":"2015","author":"Schmidt-Hansen M","year":"2015","unstructured":"Schmidt-Hansen M, Bromham N, Taubert M,  Buprenorphine for treating cancer pain. Cochrane Database Syst Rev 2015;2015:CD009596."},{"key":"B55","series-title":"J Pain Symptom Manage","first-page":"e525","article-title":"The effectiveness and safety of buprenorphine in palliative care: a systematic review of randomized controlled trials, prospective and retrospective studies","volume":"71","author":"Jose V","year":"2026","unstructured":"Jose V, Thekkekara R, Stuckler D, Greminger A. The effectiveness and safety of buprenorphine in palliative care: a systematic review of randomized controlled trials, prospective and retrospective studies. J Pain Symptom Manage 2026;71:e525\u2013539."},{"key":"B56","series-title":"J Opioid Manag","first-page":"85","article-title":"Transdermal opioids for cancer pain control in patients with renal impairment","volume":"10","author":"Melilli G","year":"2014","unstructured":"Melilli G, Samolsky Dekel BG, Frenquelli C,  Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag 2014;10:85\u201393."},{"key":"B57","article-title":"Buprenorphine transdermal system. Prescribing information","year":"2019","unstructured":"Buprenorphine transdermal system. Prescribing information. Purdue Pharma LP; 2019. Accessed April 14, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021306s035lbl.pdf"},{"key":"B58","series-title":"Ann Intern Med","first-page":"388","article-title":"The use of opioids in the management of chronic pain: synopsis of the 2022 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline","volume":"176","author":"Sandbrink F","year":"2023","unstructured":"Sandbrink F, Murphy JL, Johansson M,  The use of opioids in the management of chronic pain: synopsis of the 2022 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med 2023;176:388\u2013397."},{"key":"B59","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2013 United States,","volume":"71","author":"Dowell D","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM,  CDC clinical practice guideline for prescribing opioids for pain \u2013 United States, 2022. MMWR Recomm Rep 2022;71:1\u201395."},{"key":"B60","series-title":"CA Cancer J Clin","first-page":"286","article-title":"Opioid analgesics for nociceptive cancer pain: a comprehensive review","volume":"74","author":"Abdel Shaheed C","year":"2024","unstructured":"Abdel Shaheed C, Hayes C, Maher CG,  Opioid analgesics for nociceptive cancer pain: a comprehensive review. CA Cancer J Clin 2024;74:286\u2013313."},{"key":"B61","series-title":"J Pain Symptom Manage","first-page":"223","article-title":"Shifting views on cancer pain management: a systematic review and network meta-analysis","volume":"68","author":"Imkamp MSV","year":"2024","unstructured":"Imkamp MSV, Theunissen M, Viechtbauer W,  Shifting views on cancer pain management: a systematic review and network meta-analysis. J Pain Symptom Manage 2024;68:223\u2013236."},{"key":"B62","series-title":"J Natl Compr Canc Netw","first-page":"992","article-title":"Adult cancer pain","volume":"11","author":"Swarm RA","year":"2013","unstructured":"Swarm RA, Abernethy AP, Anghelescu DL,  Adult cancer pain. J Natl Compr Canc Netw 2013;11:992\u20131022."},{"key":"B63","article-title":"NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain","author":"Swarm RA","year":"2025","unstructured":"Swarm RA, Youngwerth JM, Agne JL,  NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain. Version 2.2025. Accessed November 20, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B64","article-title":"WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents.","year":"2025","unstructured":"World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Accessed March 31, 2025. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789241550390"},{"key":"B65","article-title":"The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th List","year":"2025","unstructured":"World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th List. Accessed September 11, 2025. Available at: https:\/\/www.who.int\/publications\/i\/item\/B09474"},{"key":"B66","article-title":"Palliative care pain and symptom control guidelines for adults","year":"2025","unstructured":"Greater Manchester Health and Social Care Partnership. Palliative care pain and symptom control guidelines for adults. Accessed March 31, 2025. Available at: https:\/\/www.england.nhs.uk\/north-west\/wp-content\/uploads\/sites\/48\/2020\/01\/Palliative-Care-Pain-and-Symptom-Control-Guidelines.pdf"},{"key":"B67","article-title":"guidelines on converting doses of opioid analgesics for adult use 2023","unstructured":"Health and Social Care in Northern Ireland. Northern Ireland guidelines on converting doses of opioid analgesics for adult use 2023. Accessed March 31, 2025. Available at: https:\/\/bso.hscni.net\/wp-content\/uploads\/2023\/10\/Opioid-Equivalence-Guidance-2023.pdf"},{"key":"B68","article-title":"Scottish palliative care guidelines","unstructured":"Healthcare Improvement Scotland. Scottish palliative care guidelines. Accessed March 31, 2025. Available at: https:\/\/www.palliativecareguidelines.scot.nhs.uk\/"},{"key":"B69","series-title":"Clin Transl Oncol","first-page":"97","article-title":"SEOM clinical guideline for treatment of cancer pain","volume":"20","author":"Jara C","year":"2018","unstructured":"Jara C, Del Barco S, Gr\u00e1valos C,  SEOM clinical guideline for treatment of cancer pain. Clin Transl Oncol 2018;20:97\u2013107."},{"key":"B70","article-title":"Palliative care for patients with incurable cancer","year":"2025","unstructured":"German Guideline Programme in Oncology (GGPO). Palliative care for patients with incurable cancer. Accessed March 31, 2025. Available at: https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Palliativmedizin\/Version_2\/GGPO_Palliative_Care_ShortVersion_2.2.pdf"},{"key":"B71","article-title":"Pain","year":"2025","unstructured":"Canadian Cancer Society. Pain. Accessed March 31, 2025. Available at: https:\/\/cancer.ca\/en\/treatments\/side-effects\/pain"},{"key":"B72","article-title":"Opioid conversion ratios: guidance document","year":"2025","unstructured":"Safer Care Victoria. Opioid conversion ratios: guidance document. Accessed March 31, 2025. Available at: https:\/\/www.safercare.vic.gov.au\/sites\/default\/files\/2021-02\/GUIDANCE_Opioid%20Conversion%20FINAL_0.pdf"},{"key":"B73","series-title":"J Palliat Med","first-page":"1095","article-title":"Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese Society of Palliative Medicine","volume":"25","author":"Mawatari H","year":"2022","unstructured":"Mawatari H, Shinjo T, Morita T,  Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese Society of Palliative Medicine. J Palliat Med 2022;25:1095\u20131114."},{"key":"B74","series-title":"J Clin Oncol","first-page":"914","article-title":"Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline","volume":"41","author":"Paice JA","year":"2023","unstructured":"Paice JA, Bohlke K, Barton D,  Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol 2023;41:914\u2013930."},{"key":"B75","article-title":"Cancer pain: clinical practice guideline","year":"2025","unstructured":"Alberta Health Services. Cancer pain: clinical practice guideline. Accessed March 31, 2025. Available at: https:\/\/www.albertahealthservices.ca\/assets\/info\/hp\/cancer\/if-hp-cancer-guide-supp012-cancer-pain.pdf"},{"key":"B76","article-title":"Cancer pain management in adults clinical guidelines","year":"2025","unstructured":"Cancer Council Australia. Cancer pain management in adults clinical guidelines. Accessed March 31, 2025. Available at: https:\/\/www.cancer.org.au\/clinical-guidelines\/cancer-pain-management"},{"key":"B77","article-title":"Palliative care for the patient with incurable cancer or advanced disease \u2013 part 2: pain and symptom management","year":"2025","unstructured":"Medical Services Commission of British Columbia, Guidelines and Protocols Advisory Committee. Palliative care for the patient with incurable cancer or advanced disease \u2013 part 2: pain and symptom management. Accessed March 31, 2025. Available at: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/bc-guidelines\/palliative-pain-management"},{"key":"B78","series-title":"J Support Oncol","first-page":"209","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis MP","year":"2012","unstructured":"Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012;10:209\u2013219."},{"key":"B79","series-title":"J Opioid Manag","first-page":"285","article-title":"Patients\u2019 perceptions of buprenorphine use receiving treatment for cancer","volume":"19","author":"Yeung A","year":"2023","unstructured":"Yeung A, Galvez-Peralta M, Apopa J,  Patients\u2019 perceptions of buprenorphine use receiving treatment for cancer. J Opioid Manag 2023;19:285\u2013289."},{"key":"B80","series-title":"J Pain Symptom Manage","first-page":"119","article-title":"Barriers to buprenorphine prescribing for opioid use disorder in hospice and palliative care","volume":"64","author":"Ho JJ","year":"2022","unstructured":"Ho JJ, Jones KF, Sager Z,  Barriers to buprenorphine prescribing for opioid use disorder in hospice and palliative care. J Pain Symptom Manage 2022;64:119\u2013127."},{"key":"B81","article-title":"Cancer pain (adults): pharmacological management (clinical guideline 140)","year":"2025","unstructured":"National Institute for Health and Care Excellence (NICE). Cancer pain (adults): pharmacological management (clinical guideline 140). Accessed March 31,02025. Available at: https:\/\/www.nice.org.uk\/guidance\/cg140"},{"key":"B82","series-title":"Ann Med Surg (Lond)","first-page":"44","article-title":"NICE opioids in palliative care (clinical guideline 140) \u2013 a guideline summary","volume":"1","author":"Teoh PJ","year":"2012","unstructured":"Teoh PJ, Camm CF. NICE opioids in palliative care (clinical guideline 140) \u2013 a guideline summary. Ann Med Surg (Lond) 2012;1:44\u201348."},{"key":"B83","series-title":"Clin Pharmacol Ther","first-page":"569","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh SL","year":"1994","unstructured":"Walsh SL, Preston KL, Stitzer ML,  Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569\u2013580."},{"key":"B84","series-title":"Clin Ther","first-page":"225","article-title":"Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study","volume":"27","author":"Sittl R","year":"2005","unstructured":"Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 2005;27:225\u2013237."},{"key":"B85","series-title":"Palliat Med","first-page":"504","article-title":"Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review","volume":"25","author":"Mercadante S","year":"2011","unstructured":"Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011;25:504\u2013515."},{"key":"B86","series-title":"J Pain Symptom Manage","first-page":"e141","article-title":"Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline clinical insights","volume":"71","author":"Davis MP","year":"2026","unstructured":"Davis MP, Bohlke K, Davies A. Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline clinical insights. J Pain Symptom Manage 2026;71:e141\u2013144."},{"key":"B87","series-title":"Pain Med","first-page":"1109","article-title":"Conversion of schedule II opioids to buprenorphine buccal film: a retrospective analysis","volume":"22","author":"Zimmerman A","year":"2021","unstructured":"Zimmerman A, Bikdash R, Rauck R. Conversion of schedule II opioids to buprenorphine buccal film: a retrospective analysis. Pain Med 2021;22:1109\u20131115."},{"key":"B88","series-title":"Drug Alcohol Depend","first-page":"109013","article-title":"Analysis of genetic and clinical factors associated with buprenorphine response","volume":"227","author":"Crist RC","year":"2021","unstructured":"Crist RC, Vickers-Smith R, Kember RL,  Analysis of genetic and clinical factors associated with buprenorphine response. Drug Alcohol Depend 2021;227:109013."},{"key":"B89","series-title":"Int J Neuropsychopharmacol","first-page":"89","article-title":"A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder","volume":"24","author":"Kranzler HR","year":"2021","unstructured":"Kranzler HR, Lynch KG, Crist RC,  A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder. Int J Neuropsychopharmacol 2021;24:89\u201396."},{"key":"B90","article-title":"Buprenorphine buccal film. Prescribing information. Collegium Pharmaceuticals","year":"2023","unstructured":"Buprenorphine buccal film. Prescribing information. Collegium Pharmaceuticals; 2023. Accessed March 28, 2025. Available at: https:\/\/www.belbuca.com\/pdfs\/belbuca-prescribing-info.pdf"},{"key":"B91","series-title":"J Am Dent Assoc","first-page":"561","article-title":"Orally dissolving buprenorphine for opioid use disorder linked to caries","volume":"155","author":"Segelnick SL","year":"2024","unstructured":"Segelnick SL, Weinberg MA. Orally dissolving buprenorphine for opioid use disorder linked to caries. J Am Dent Assoc 2024;155:561\u2013564."},{"key":"B92","series-title":"Curr Drug Saf","first-page":"261","article-title":"Dental disorders reported to the FDA adverse event reporting system in association with buprenorphine: an analysis by ingredient composition and route of administration","volume":"19","author":"Woods RH","year":"2024","unstructured":"Woods RH. Dental disorders reported to the FDA adverse event reporting system in association with buprenorphine: an analysis by ingredient composition and route of administration. Curr Drug Saf 2024;19:261\u2013267."},{"key":"B93","series-title":"Clin Ther","first-page":"299","article-title":"Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy","volume":"20","author":"Wilson DE","year":"1998","unstructured":"Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998;20:299\u2013306."},{"key":"B94","article-title":"Buprenorphine for pain management: pros vs cons in the hospice population","year":"2025","unstructured":"ProCare HospiceCare. Buprenorphine for pain management: pros vs cons in the hospice population. Accessed September 11, 2025. Available at: https:\/\/www.procarehospicecare.com\/buprenorphine-for-pain-management-pros-vs-cons-in-the-hospice-population"},{"key":"B95","series-title":"J Pain Symptom Manage","first-page":"e582","article-title":"Assessing provider barriers to use of buprenorphine for cancer-related pain","volume":"69","author":"Rahman I","year":"2025","unstructured":"Rahman I, AuBuchon K, McElreath K,  Assessing provider barriers to use of buprenorphine for cancer-related pain. J Pain Symptom Manage 2025;69:e582\u2013583."},{"key":"B96","series-title":"J Pain Symptom Manage","first-page":"e330","article-title":"Providers' barriers to buprenorphine prescribing for cancer-related pain","volume":"69","author":"AuBuchon KE","year":"2025","unstructured":"AuBuchon KE, Boanca KM, Muthineni N,  Providers' barriers to buprenorphine prescribing for cancer-related pain. J Pain Symptom Manage 2025;69:e330\u2013336."},{"key":"B97","series-title":"JAMA Intern Med","first-page":"372","article-title":"Buprenorphine, pain, and opioid use in patients taking high-dose long-term opioids: a randomized clinical trial","volume":"185","author":"Becker WC","year":"2025","unstructured":"Becker WC, Seal KH, Nelson DB,  Buprenorphine, pain, and opioid use in patients taking high-dose long-term opioids: a randomized clinical trial. JAMA Intern Med 2025;185:372\u2013381."},{"key":"B98","series-title":"Transl Psychiatry","first-page":"20","article-title":"Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records","volume":"14","author":"Niarchou M","year":"2024","unstructured":"Niarchou M, Sanchez-Roige S, Reddy IA,  Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records. Transl Psychiatry 2024;14:20."},{"key":"B99","series-title":"J Pain Symptom Manage","first-page":"e138","article-title":"Creating a palliative care clinic for patients with cancer pain and substance use disorder","volume":"68","author":"Kale SS","year":"2024","unstructured":"Kale SS, Tosto GD, Rush LJ,  Creating a palliative care clinic for patients with cancer pain and substance use disorder. J Pain Symptom Manage 2024;68:e138\u2013145."},{"key":"B100","series-title":"J Am Pharm Assoc (2003)","first-page":"102319","article-title":"Community pharmacy-based buprenorphine programs and pharmacists\u2019 roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: a systematic review","volume":"65","author":"Rawal S","year":"2025","unstructured":"Rawal S, Welsh JW, Yarbrough CR,  Community pharmacy-based buprenorphine programs and pharmacists\u2019 roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: a systematic review. J Am Pharm Assoc (2003) 2025;65:102319."},{"key":"B101","series-title":"J Am Pharm Assoc (2003)","first-page":"1606","article-title":"North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter D","year":"2022","unstructured":"Carpenter D, Lambert KV, Harless JC,  North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes. J Am Pharm Assoc (2003) 2022;62:1606\u20131614."},{"key":"B102","series-title":"Pain Med","first-page":"S19","article-title":"Patient experiences navigating chronic pain management in an integrated health care system: a qualitative investigation of women and men","volume":"19","author":"Driscoll MA","year":"2018","unstructured":"Driscoll MA, Knobf MT, Higgins DM,  Patient experiences navigating chronic pain management in an integrated health care system: a qualitative investigation of women and men. Pain Med 2018;19(Suppl 1):S19\u201329."},{"key":"B103","series-title":"N Engl J Med","first-page":"703","article-title":"When prescribing isn't enough \u2013 pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper HLF","year":"2020","unstructured":"Cooper HLF, Cloud DH, Young AM, Freeman PR. When prescribing isn't enough \u2013 pharmacy-level barriers to buprenorphine access. N Engl J Med 2020;383:703\u2013705."},{"key":"B104","series-title":"Int J Drug Policy","first-page":"102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper HL","year":"2020","unstructured":"Cooper HL, Cloud DH, Freeman PR,  Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy 2020;85:102701."},{"key":"B105","series-title":"J Addict Med","first-page":"68","article-title":"A brief online training to address pharmacists\u2019 willingness to dispense buprenorphine","volume":"18","author":"Carpenter D","year":"2024","unstructured":"Carpenter D, Mashburn P, Viracola C,  A brief online training to address pharmacists\u2019 willingness to dispense buprenorphine. J Addict Med 2024;18:68\u201370."},{"key":"B106","series-title":"Support Care Cancer","first-page":"1","article-title":"Abstracts for MASCC\/ISOO Annual Meeting 2022","volume":"30","author":"Davis M","year":"2022","unstructured":"Davis M, Maybach A, Teoli D. Abstracts for MASCC\/ISOO Annual Meeting 2022. Support Care Cancer 2022;30(Suppl 1):1\u2013207."},{"key":"B107","series-title":"Blood","first-page":"2568","article-title":"\u201cBuprenorphine, it works so differently\u201d: adults with sickle cell disease describe their experiences transitioning to buprenorphine for treatment of chronic pain","volume":"140","author":"Loeser PC","year":"2022","unstructured":"Loeser PC, Early ML, Carroll CP,  \u201cBuprenorphine, it works so differently\u201d: adults with sickle cell disease describe their experiences transitioning to buprenorphine for treatment of chronic pain. Blood 2022;140(Suppl 1):2568\u20132569."},{"key":"B108","series-title":"Anesth Analg","first-page":"1779","article-title":"Case series of successful postoperative pain management in buprenorphine maintenance therapy patients","volume":"125","author":"Leighton BL","year":"2017","unstructured":"Leighton BL, Crock LW. Case series of successful postoperative pain management in buprenorphine maintenance therapy patients. Anesth Analg 2017;125:1779\u20131783."},{"key":"B109","series-title":"Pain Med","first-page":"714","article-title":"Understanding buprenorphine for use in chronic pain: expert opinion","volume":"21","author":"Webster L","year":"2020","unstructured":"Webster L, Gudin J, Raffa RB,  Understanding buprenorphine for use in chronic pain: expert opinion. Pain Med 2020;21:714\u2013723."},{"key":"B110","series-title":"Pain","first-page":"309","article-title":"Opioid-induced constipation in patients with cancer: a \u201creal-world,\u201d multicentre, observational study of diagnostic criteria and clinical features","volume":"162","author":"Davies A","year":"2021","unstructured":"Davies A, Leach C, Butler C,  Opioid-induced constipation in patients with cancer: a \u201creal-world,\u201d multicentre, observational study of diagnostic criteria and clinical features. Pain 2021;162:309\u2013318."},{"key":"B111","series-title":"J Opioid Manag","first-page":"543","article-title":"Outpatient cross-titration to buprenorphine for chronic pain: a retrospective analysis","volume":"19","author":"Ito S","year":"2023","unstructured":"Ito S, Welsh M, Bockman C,  Outpatient cross-titration to buprenorphine for chronic pain: a retrospective analysis. J Opioid Manag 2023;19:543\u2013554."},{"key":"B112","series-title":"JAMA Netw Open","first-page":"e2124152","article-title":"Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review","volume":"4","author":"Powell VD","year":"2021","unstructured":"Powell VD, Rosenberg JM, Yaganti A,  Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review. JAMA Netw Open 2021;4:e2124152."},{"key":"B113","series-title":"Pharmacoepidemiol Drug Saf","first-page":"733","article-title":"A synthesis of oral morphine equivalents (OME) for opioid utilisation studies","volume":"25","author":"Nielsen S","year":"2016","unstructured":"Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf 2016;25:733\u2013737."},{"key":"B114","series-title":"Pain Pract","first-page":"123","article-title":"Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients","volume":"7","author":"Freye E","year":"2007","unstructured":"Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract 2007;7:123\u2013129."},{"key":"B115","series-title":"Pain Med","first-page":"899","article-title":"Evaluation of the tolerability of switching patients on chronic full \u03bc-opioid agonist therapy to buccal buprenorphine","volume":"17","author":"Webster L","year":"2016","unstructured":"Webster L, Gruener D, Kirby T,  Evaluation of the tolerability of switching patients on chronic full \u03bc-opioid agonist therapy to buccal buprenorphine. Pain Med 2016;17:899\u2013907."},{"key":"B116","series-title":"Ann Intern Med","first-page":"70","article-title":"Switching from high-dose, long-term opioids to buprenorphine: a case series","volume":"173","author":"Becker WC","year":"2020","unstructured":"Becker WC, Frank JW, Edens EL. Switching from high-dose, long-term opioids to buprenorphine: a case series. Ann Intern Med 2020;173:70\u201371."},{"key":"B117","series-title":"J Palliat Med","first-page":"145","article-title":"Buprenorphine microdosing for the pain and palliative care clinician","volume":"25","author":"Quirk K","year":"2022","unstructured":"Quirk K, Stevenson M. Buprenorphine microdosing for the pain and palliative care clinician. J Palliat Med 2022;25:145\u2013154."},{"key":"B118","series-title":"Can J Pain","first-page":"2310811","article-title":"Low-dose initiation of buprenorphine\/naloxone for the management of chronic noncancer pain in patients on long-term opioid therapy: a case series","volume":"8","author":"Rattanavong M","year":"2024","unstructured":"Rattanavong M, Kwan D, Jorgenson D,  Low-dose initiation of buprenorphine\/naloxone for the management of chronic noncancer pain in patients on long-term opioid therapy: a case series. Can J Pain 2024;8:2310811."},{"key":"B119","series-title":"Curr Med Res Opin","first-page":"1517","article-title":"The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus","volume":"25","author":"Pergolizzi JV","year":"2009","unstructured":"Pergolizzi JV, Mercadante S, Echaburu AV,  The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517\u20131528."},{"key":"B120","series-title":"PLoS One","first-page":"e0241362","article-title":"Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block","volume":"15","author":"Tran PN","year":"2020","unstructured":"Tran PN, Sheng J, Randolph AL,  Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. PLoS One 2020;15:e0241362."},{"key":"B121","series-title":"Arch Intern Med","first-page":"2469","article-title":"QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial","volume":"167","author":"Wedam EF","year":"2007","unstructured":"Wedam EF, Bigelow GE, Johnson RE,  QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167:2469\u20132475."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/6\/article-e257132.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/6\/article-e257132.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/6\/article-e257132.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:47:58Z","timestamp":1781527678000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/6\/article-e257132.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":242,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7132","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}